Smartphone-delivered Scheduled Smoking With Compliance Facilitation as an Adjunct Cessation Therapy: a Feasibility Study

Sponsor
M.D. Anderson Cancer Center (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05763771
Collaborator
(none)
75
1
2
39
1.9

Study Details

Study Description

Brief Summary

To collect user experience data for a smartphone app that is designed to help people reduce or quit smoking and to learn if the app, combined with nicotine patches, can help people quit smoking.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Smart Phone App
  • Other: NIcotine Patches
N/A

Detailed Description

Objectives:

We propose to develop a mobile smoking intervention termed COmpliance-facilitated Scheduled Smoking Reduction (COSSR) delivered as a smartphone app. Through the proposed research as a pilot study, we want to identify the effect size of the proposed COSSR

intervention. We will pursue the following aims:

Aim 1:

Develop the COSSR app and evaluate the app's usability. In this aim, our first objective is to develop the COSSR app, and our second objective is to evaluate the app's usability, making sure that our app's core features are working, such as generating personalized smoking schedules, recording smoking, and taking carbon monoxide (CO) measures using the portable CO devices. We will recruit 15 participants from across the state of Texas to test our app for 4 weeks.

Aim 2:

Evaluate COSSR's preliminary effects on smoking cessation. In this aim, we will recruit participants (n=60) remotely from across the entire state of Texas to evaluate COSSR's effects on smoking cessation. Participants will be randomly assigned to either the control or the COSSR group. Both groups include the usual care treatment (self-help material and nicotine patches). In the COSSR group, they will use the app to reduce their smoking before quitting, and use 3-week pre-cessation nicotine patches.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
75 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Smartphone-delivered Scheduled Smoking With Compliance Facilitation as an Adjunct Cessation Therapy: a Feasibility Study
Anticipated Study Start Date :
Aug 31, 2023
Anticipated Primary Completion Date :
Dec 1, 2024
Anticipated Study Completion Date :
Dec 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Part 1

Participants will use the app for 4 weeks, during which participants will follow a smoking schedule on the app to help you reduce your cigarette consumption

Behavioral: Smart Phone App
Collection of data

Other: NIcotine Patches
Place on the skin

Experimental: Part 2

Participants will also use the app for the duration of the study (about 3 months). Participants will be asked to record your smoking using the app and complete online surveys

Behavioral: Smart Phone App
Collection of data

Other: NIcotine Patches
Place on the skin

Outcome Measures

Primary Outcome Measures

  1. Application (App) Usability Questionnaire [through completion of study; an average of 1 year.]

    Scale Scores (1-5) 1-strongly disagree, 2-disagree, 3-neither disagree nor agree, 4-agree and 5-strongly agree

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age: 18 years old or older

  • Smoking: an average of 10 or more cigarettes, little cigars, or cigarillos combined per day within the past 30 days preceding the phone screen

  • Expired carbon monoxide (CO): > 6 ppm

  • Can install and run the study app on their Android smartphone, or agree to use the study smartphone loaned from the research team

  • Agree to return the study smartphone if the participant loans one from the research team

  • Willing to reduce smoking (Aim 1)

  • Seeking smoking cessation treatment (Aim 2)

  • Fluency in spoken and written English

  • Agree to be treated via telehealth (live audio-video conference and phone) and to be contacted via text and/or email

  • Provide informed consent and agree to all assessments and study procedures

  • Willing to refrain from the use of other nicotine/tobacco products for the duration of the study

  • Willing to refrain from the use of marijuana, prescription medications not prescribed to the participant, and illegal drugs

Exclusion Criteria:
  • Taking psychotropic, anticonvulsive, or narcotic medication

  • Meet criteria for a current major depressive episode or suicidality according to the PHQ

  • Involved in current and imminent (within the next 45 days) smoking cessation activity

  • Women who are pregnant or breastfeeding

  • Shares the same address as a currently enrolled participant

  • Unwilling to use or allergic to nicotine patches (Aim 2)

  • Considered by the investigator to be an unsuitable or unstable candidate, such as those who appear to have cognitive impairment, and those who reside in a shelter, group/recovery facility, or treatment facility

  • Any plans to move out of the state in the next 6 months

  • Using marijuana, prescription medications not prescribed to the participant, and illegal drugs on a daily basis

  • Have experienced abnormal heart rhythms or cardiovascular disease, such as stroke, chest pain, and heart attack, in the last month (Aim 2)

Contacts and Locations

Locations

Site City State Country Postal Code
1 M D Anderson Cancer Center Houston Texas United States 77030

Sponsors and Collaborators

  • M.D. Anderson Cancer Center

Investigators

  • Principal Investigator: Yong Cui, PHD, M.D. Anderson Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT05763771
Other Study ID Numbers:
  • 2022-0772
  • NCI-2023-01983
First Posted:
Mar 10, 2023
Last Update Posted:
Mar 10, 2023
Last Verified:
Feb 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 10, 2023